Why the Decline in Pharma R&D?

For a few decades now there has been a narrative in the pharmaceutical sector that R&D productivity has been steadily declining: thanks to a lack of low-hanging fruit, blockbuster drugs have been harder and harder to find. AI promises a...

4 weeks ago
R&D,AI & ML,News

Why the Decline in Pharma R&D?

For a few decades now there has been a narrative in the pharmaceutical sector that R&D productivity has been steadily declining: thanks to a lack of low-hanging fruit, blockbuster drugs have been harder and harder to find. AI promises a...

4 weeks ago

Uses for AI in Pharma R&D

AI is by far the biggest buzzword in pharma today - but unlike many other high-profile trends, AI has the potential to rapidly and totally transform the sector forever, speeding up processes, automating basic tasks and making sense of the...

4 weeks ago
R&D,Bioinformatics,AI & ML,News

Uses for AI in Pharma R&D

AI is by far the biggest buzzword in pharma today - but unlike many other high-profile trends, AI has the potential to rapidly and totally transform the sector forever, speeding up processes, automating basic tasks and making sense of the...

4 weeks ago

Weekly News Round-Up – 14/8/20

In the news this week, the race for a vaccine begins to near its conclusion as the U.S. and U.K. continue to buy up supplies of promising vaccines, and Moderna comes under criticism for its steep prices that make the...

1 month ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-Up – 14/8/20

In the news this week, the race for a vaccine begins to near its conclusion as the U.S. and U.K. continue to buy up supplies of promising vaccines, and Moderna comes under criticism for its steep prices that make the...

1 month ago

Key Challenges in Oncology and Bioinformatics

This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Oncology/Bioinformatics events,...

1 month ago
Oncology,R&D,Bioprocess,AI & ML,Biology,News

Key Challenges in Oncology and Bioinformatics

This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Oncology/Bioinformatics events,...

1 month ago

The Future of Clinical Trials and Pharmacovigilance

This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Clinical Trials/Pharmacovigilance...

1 month ago
Pharmacovigilance,Clinical Development,Clinical Operations,News

The Future of Clinical Trials and Pharmacovigilance

This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Clinical Trials/Pharmacovigilance...

1 month ago

Weekly News Round-up – 7/8/20

In the news this week, vaccine deals are afoot on either side of the Atlantic: both the U.K. and U.S. governments have signed deals with Sanofi and GSK for doses of their COVID-19 vaccine, while the UK has also requested...

1 month ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 7/8/20

In the news this week, vaccine deals are afoot on either side of the Atlantic: both the U.K. and U.S. governments have signed deals with Sanofi and GSK for doses of their COVID-19 vaccine, while the UK has also requested...

1 month ago

Weekly News Round-up – 17/7/20

In the news this week, despite significant alarms recently that GSK’s belantamab mafodotin could endanger patients’ eyes, the multiple myeloma drug has been approved by expert advisers. In other news, Novartis promises to make no profit from 15 of its COVID...

2 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 17/7/20

In the news this week, despite significant alarms recently that GSK’s belantamab mafodotin could endanger patients’ eyes, the multiple myeloma drug has been approved by expert advisers. In other news, Novartis promises to make no profit from 15 of its COVID...

2 months ago

Weekly News Round-up – 10/7/20

In the news this week, the Trump Administration has made another deal to acquire all initial doses of a potential COVID-19 drug, in this case Regeneron’s REGN-COV2. This follows their acquisition of the first batches of Gilead’s remdesivir last week....

2 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 10/7/20

In the news this week, the Trump Administration has made another deal to acquire all initial doses of a potential COVID-19 drug, in this case Regeneron’s REGN-COV2. This follows their acquisition of the first batches of Gilead’s remdesivir last week....

2 months ago

Weekly News Round-up – 3/7/20

Big news this week, with the U.S. administration buying up remdesivir’s stock for the next three months, ensuring no other country will receive any. In other news, Pfizer and BioNTech’s own covid drug has shown promising results in early trials,...

3 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 3/7/20

Big news this week, with the U.S. administration buying up remdesivir’s stock for the next three months, ensuring no other country will receive any. In other news, Pfizer and BioNTech’s own covid drug has shown promising results in early trials,...

3 months ago

Weekly News Round-up – 19/6/20

This week, pharma begins looking beyond the imminent struggle against Covid-19’s initial challenges to the further horizon, and the dreaded second wave. Vaccine demand in a number of countries is rising in preparation of easing lockdowns, while Gilead’s remdesivir starts...

3 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 19/6/20

This week, pharma begins looking beyond the imminent struggle against Covid-19’s initial challenges to the further horizon, and the dreaded second wave. Vaccine demand in a number of countries is rising in preparation of easing lockdowns, while Gilead’s remdesivir starts...

3 months ago